Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 91.44 mg (equivalent: atomoxetine, qty 91.44 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 68.58 mg (equivalent: atomoxetine, qty 68.58 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 45.72 mg (equivalent: atomoxetine, qty 40 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 28.58 mg (equivalent: atomoxetine, qty 25 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 20.57 mg (equivalent: atomoxetine, qty 18 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; maize starch; pregelatinised maize starch; titanium dioxide; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 11.43 mg (equivalent: atomoxetine, qty 10 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Estats Units - anglès - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 10 mg - pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including atomoxetine, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for adhd medications at 1-866-961-2388 or visiting https://womensmentalhealth.org/adhd-medications/ . risk summary available published studies with atomoxetine use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. some animal reproduction studies of atomoxetine had adverse developmental outcomes. one of 3 studies in pregnant rabbits dosed during organogenesis resulted in decreased live fetuses and an increase in early resorptions, as well as slight increases in the incidences of atypical origin of carotid artery and absent subclavian artery. these effects were observed at plasma levels (auc) 3 times and 0.4 times the human plasma levels in e

Estats Units - anglès - NLM (National Library of Medicine)

sun pharma global fze - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 10 mg

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - atomoxetine hydrochloride -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - atomoxetine hydrochloride -